Journal

Biosensors and Bioelectronics

Papers (21)

Sensitive phenotyping of serum extracellular vesicles on a SERS-microfluidic platform for early-stage clinical diagnosis of ovarian carcinoma

Ovarian carcinoma (OvCa) poses a severe threat to women's health due to its high mortality rate and lack of efficient early diagnosis approach. There is evidence to suggest that nanosized small extracellular vesicles (sEVs) which carrying cell-specific components from OvCa can serve as potential diagnostic biomarkers. Herein, we reported a Surface-enhanced Raman Scattering (SERS)-multichannel microchip for sEVs (S-MMEV) assay to investigate the phenotype changes of sEVs. The microchip composed of seven microchannels, which enabled the parallel detection of multiple biomarkers to improve the detection accuracy. Using SERS probes conjugated with antibodies recognizing different biomarkers including ubiquitous EV biomarkers (i.e., tetraspanins; CD9, CD81) and putative OvCa tumor biomarkers (i.e. EpCAM, CD24, CA125, EGFR), we successfully analyzed the phenotypic changes of sEVs and accurately differentiated OvCa patients from healthy controls, even at early stage (I-II), with high sensitivity, high specificity and an area under the curve value of 0.9467. Additionally, the proposed approach exhibited higher sensitivity than conventional methods, demonstrating the efficiency of precise detection from cell culture and clinical samples. Collectively, the developed EV phenotyping approach S-MMEV could serve as a potential tool to achieve the early clinical diagnosis of OvCa for further precise diagnosis and personal treatment monitoring.

An electrochemical biosensor for sensitive detection of CKAP4 with application to the diagnosis of ovarian cancer

Cytoskeletal remodeling is crucial in tumor progression and metastasis, with cytoskeleton-associated protein 4 (CKAP4) being a key protein involved this process; however, its detection remains a challenge. In this paper, we report a solid-state electrochemistry-enhanced biosensor based on Cu-TCPP nanosheets for sensitive detection of CKAP4. In the meantime, the proposed biosensor can present high specificity in CKAP4 recognition. Specifically, upon recognition of the target, the designed catalytic hairpin assembly (CHA) reaction is successfully initiated, generating lots of DNA duplexes, which can be cleaved by Exo III to release numerous truncated thiolated signal DNA (sDNA). Subsequently, the generated sDNA is introduced to a high-conductivity electrode surface modified with Cu-TCPP nanosheets which are loaded with methylene blue. Moreover, the introduction of sDNA triggers ligand displacement via competitive coordination on this surface, thereby forming non-electroactive Cu-sDNA complexes, which significantly modulates the current signals, enabling sensitive quantification of CKAP4 levels. The biosensor may achieve a low detection limit of 0.30 pg/mL, with a broad linear range covering five orders of magnitude, and exhibits satisfying anti-interference ability in complex biological matrices. Furthermore, it displays outstanding discriminatory accuracy in differentiating ovarian cancer patient samples from healthy controls, showing great potential for cancer diagnosis.

Integration of label-free surface enhanced Raman spectroscopy (SERS) of extracellular vesicles (EVs) with Raman tagged labels to enhance ovarian cancer diagnostics

We report a proof-of-concept diagnostic strategy that integrates multiplexed Raman-tagged antibody labeling with label-free surface-enhanced Raman spectroscopy (SERS) and machine learning (ML) to improve the detection of ovarian cancer via extracellular vesicles (EVs). EVs were isolated from patient plasma using size-exclusion chromatography and labeled with polyyne-based Raman tags targeting three ovarian cancer biomarkers: CA-125, HE4, and CA-19-9. Labeled and unlabeled EVs were deposited onto SERS-active substrates, and spectra were collected using a custom confocal Raman microscope. Incorporating the tag-derived signal into SERS analysis enhanced interpretability and added molecular specificity. We evaluated classification performance using various ML models applied to spectral datasets from a cohort of ovarian cancer patients and healthy controls. Combined use of the Raman tag and label-free regions improved classification accuracy compared to either modality alone. Notably, support vector machine (SVM) achieved over 95 % accuracy, sensitivity, and specificity. Compared to ELISA, our SERS platform demonstrated improved sensitivity in detecting EV-associated biomarkers from small sample volumes. This approach addresses a key limitation of SERS-based diagnostics by linking spectral features to known biomarkers, offering improved transparency and performance in ML-enabled liquid biopsy.

Nano biosensor unlocks tumor derived immune signals for the early detection of ovarian cancer

Ovarian cancer is a critical health issue for women nowadays. Its impact is significant because of its high mortality rate (324,603 worldwide), late-stage diagnosis and poor survival rate. Lack of screening tests, vague symptoms, misdiagnosis, and age factor makes it even more difficult to detect. Neutrophils, a subset of immune cells, undergo tumor-specific changes as ovarian cancer progresses inside ovarian tumour microenvironment. Therefore, monitoring the time-specific activity of neutrophils in circulation has the potential to aid in the diagnosis of ovarian cancer. Most ovarian tumor-specific antigens are unknown, making it difficult to identify neutrophils associated with ovarian tumor. We present ovarian tumor-associated circulating neutrophil cell profiling as a stand-alone cancer diagnostic method using a liquid biopsy. Using a SERS-functionalized nano probe, the metabolic profiles of neutrophils from ovarian tumor interaction are detected. We demonstrate that neutrophils associated with cancer stem cells have a distinct metabolic profile and are useful in the diagnosis of early ovarian cancer. Using 5 μL of peripheral blood and an artificial neural network, the characteristics of neutrophil profiles in patient blood could distinguish cancer cohort from non-cancer (healthy) with a 90 % sensitivity and 100 % specificity. Our results demonstrate the viability of using circulating neutrophils for non-invasive cancer diagnostics.

CRISPR-Cas12a-integrated pregnancy test strip biosensors: Visual detection of telomerase and miRNA let-7a in cervical cancer diagnostics

Cervical cancer is a leading cause of female cancer-related mortality globally, and early screening based on reliable biomarkers is critical for improving prognosis. Telomerase (a key driver of cellular immortalization) and microRNA let-7a (a tumor suppressor with downregulated expression in cervical cancer) are well-validated diagnostic targets, but existing detection methods are hindered by complex procedures, high instrumentation costs, and reliance on specialized technical expertise-limiting their accessibility in resource-constrained settings. To address these limitations, we developed two novel CRISPR-Cas12a-integrated biosensors using commercially available pregnancy test strips (PTS) for instrument-free, visual readout. Both biosensors leverage a core signal mediator, probe 1 ("MB-ssDNA1-hCG"), which links CRISPR-Cas12a activation to visible color development on the PTS. The first Biosensor CRISPR-PTS-Telo detects telomerase activity in one-step without PCR: telomerase-generated (TTAGGG)n repeats activate Cas12a-crRNA1 complex, cleaving the probe 1 to release hCG, achieving a detection limit of 18 HeLa cells-comparable to sensitive laboratory assays. The second Biosensor CRISPR-PTS-let7a detects miRNA let-7a by first converting miRNA signals to Trigger DNA via Assister DNA and probe 2 ("MB-ssDNA2+Trigger"), activating Cas12a-crRNA2 complex, cleaving the probe 1 and inducing PTS coloration. This achieves a detection limit of 25.1 fM for let-7a. Validation with clinical samples (24 cervical tissues and 26 blood samples) confirmed their concordance with gold-standard methods (ELISA for telomerase, RT-qPCR for let-7a). These versatile tools hold significant potential as point-of-care testing (POCT) solutions to facilitate early, accessible cervical cancer screening.

T7-assisted special rolling circular amplification platform for point-of-care cervical cancer screening

Cervical cancer, primarily caused by high-risk human papillomavirus (HPV) infections, remains a leading cause of mortality among women in underdeveloped and developing countries. Conventional screening methods, necessitating professional equipment and trained personnel, are impractical in resource-limited settings, underscoring the need for a point-of-care (POC) detection platform. Isothermal nucleic acid amplification techniques (NAATs) are widely used in POC applications due to their cost-effectiveness and instrument-free nature. In this study, a novel one-pot dual amplification system, T7-MSSRCA was developed, by integrating the minimum secondary structure rolling circular amplification (MSS-RCA) with T7 Exonuclease. This system achieved an amplification time of 15 min and a total diagnostic time of approximately 1 h. Moreover, signal detection using both fluorescence and lateral flow assay (LFA) strips was achieved through reporter probe modifications. By employing a human chorionic gonadotropin (hCG)-modified reporter probe, the T7-MSSRCA system facilitated quantitative POC detection via pregnancy test strips. The system demonstrated impressive sensitivities for synthesized HPV16 targets, achieving 1 fM with fluorescent output and 10 fM with paper strips. When tested with 50 cervical swab samples, T7-MSSRCA exhibited a sensitivity of 0.95 and a specificity of 0.9333 compared to RT-PCR measurements.

Publisher

Elsevier BV

ISSN

0956-5663